» Articles » PMID: 35013934

Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease

Overview
Specialty Neurology
Date 2022 Jan 11
PMID 35013934
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease is associated with impairments in emotional communication including comprehension and production of facial emotional expressions, comprehension of affective prosody, and alexithymia. It is also associated with disorders of emotional experience including mood disorders (depression and anxiety), agitation/aggression, and psychosis. Agitation/aggression and psychosis are particularly disruptive, are associated with earlier institutionalization, and pose a major challenge to institutional management. Treatment of disorders of emotional experience has been primarily pharmacologic (reviewed here in detail) and has relied heavily on antipsychotic medications despite the small effect sizes demonstrated in a large number of randomized controlled trials and the prevalence of serious side effects associated with these drugs. Recent studies suggest that treatment with pimavanserin, an antipsychotic without activity at dopamine receptors, may represent an important advance for treatment of psychotic manifestations, even as the drug appears to pose significant risk. Dextromethorphan/quinidine may represent an important advance in the treatment of agitation/aggression. There is also compelling evidence that sleep disorders, which are common among patients with Alzheimer's disease and are readily treatable, may potentiate psychotic manifestations and agitation/aggression, but further studies are needed.

Citing Articles

AI-assisted neurocognitive assessment protocol for older adults with psychiatric disorders.

Diaz-Guerra D, Hernandez-Lugo M, Broche-Perez Y, Ramos-Galarza C, Iglesias-Serrano E, Fernandez-Fleites Z Front Psychiatry. 2025; 15:1516065.

PMID: 39872430 PMC: 11770049. DOI: 10.3389/fpsyt.2024.1516065.


Unexplored avenues: a narrative review of cognition and mood in postmenopausal African women with female genital circumcision/mutilation/cutting.

Kumar R, Calvo N, Einstein G Front Glob Womens Health. 2025; 5():1409397.

PMID: 39850363 PMC: 11754282. DOI: 10.3389/fgwh.2024.1409397.


Choline Metabolites Reverse Differentially the Habituation Deficit and Elevated Memory of Tau Null Drosophila.

Zerva M, Triantafylloudis C, Paspaliaris V, Skoulakis E, Papanikolopoulou K Cells. 2024; 13(9.

PMID: 38727282 PMC: 11083674. DOI: 10.3390/cells13090746.


Early ultrasonic vocalization deficits and related thyroarytenoid muscle pathology in the transgenic TgF344-AD rat model of Alzheimer's disease.

Rudisch D, Krasko M, Barnett D, Mueller K, Russell J, Connor N Front Behav Neurosci. 2024; 17:1294648.

PMID: 38322496 PMC: 10844490. DOI: 10.3389/fnbeh.2023.1294648.


Probing the relevance of the accelerated aging mouse line SAMP8 as a model for certain types of neuropsychiatric symptoms in dementia.

Bergamini G, Massinet H, Hart A, Durkin S, Pierlot G, Steiner M Front Psychiatry. 2023; 14:1054163.

PMID: 36896346 PMC: 9989166. DOI: 10.3389/fpsyt.2023.1054163.


References
1.
Nadeau S . Neural mechanisms of emotions, alexithymia, and depression. Handb Clin Neurol. 2021; 183:299-313. DOI: 10.1016/B978-0-12-822290-4.00014-1. View

2.
Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A . The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004; 63(2):214-9. DOI: 10.1212/01.wnl.0000129990.32253.7b. View

3.
Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R . A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003; 64(2):134-43. DOI: 10.4088/jcp.v64n0205. View

4.
Chi S, Yu J, Tan M, Tan L . Depression in Alzheimer's disease: epidemiology, mechanisms, and management. J Alzheimers Dis. 2014; 42(3):739-55. DOI: 10.3233/JAD-140324. View

5.
Paunescu H, Dima L, Ghita I, Coman L, Ifteni P, Fulga I . A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia. Am J Ther. 2020; 27(3):e249-e269. DOI: 10.1097/MJT.0000000000001120. View